cancer detection

Strategic Samsung Partnership GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Korea investing.com prnewswire.com. This collaboration gives Samsung “a strong foothold for expanding into the cancer screening field”, according to Jaywoo Kim, EVP of Samsung C&T prnewswire.com. GRAIL’s President of International Business, Sir Harpal Kumar, said the deal “strengthens our balance sheet and provides further cash runway” as the company